Nitrosamines Update EMA/409815/2020 Rev.22
Nitrosamines Update EMA/409815/2020 Rev.22
Regulatory Affairs Pharma & Biotech
Monday, 02 June 2025
Pablo Palomar, Senior Toxicology Officer at QbD Group
Share
\
\
X (Twitter) 
\
\
LinkedIn 
\
\
WhatsApp 
\
\
Copy link 
\
\
Mail
On 17 May 2025, the European Medicines Agency (EMA) released Revision 22 of its Nitrosamines Q&A document (EMA/409815/2020), bringing key updates for pharmaceutical manufacturers and regulatory professionals.
Play
Nitrosamines Update EMA/409815/2020 Rev.22 | Regulatory Update QbD
AI-generated audio
1:36
What is new?
In the latest EMA Q&A Rev.22 update, the same risk-based approach is now applied across all routes of administration, with the previous allowance for route-specific justifications removed.
A negative result from a well-conducted in vivo transgenic rodent (TGR) mutagenicity study (OECD 488) is now sufficient to classify N-nitrosamines as non-mutagenic impurities (NMIs), allowing control under ICH Q3A(R2)/Q3B(R2) limits.
Additionally, changes to shelf life and storage conditions to comply with interim acceptable intakes (AIs) are to be implemented without delay, following the guideline on variation classification (see Q&A 13).
These updates reflect EMA’s ongoing commitment to science-based, risk-proportionate regulation—and open new opportunities for smarter impurity control strategies.
What does this mean to you?
While this is a relatively minor update, it is particularly useful for Marketing Authorization Holders (MAHs) who were unsure about which in vivo studies to design in order to justify classifying a specific nitrosamine as a non-mutagenic impurity (NMI). It also reinforces the principle that the route of administration should not be considered when setting nitrosamine limits—offering a broader safety margin for patients
Get in touch with our experts
Should you want to discuss this more in-depth with one of our consultants, please do not hesitate to contact us.
Discover more expert content
Previous
Regulatory Affairs
27 Jan 2025
New revision to EMA Guidance documents released
Both documents, Guidance on the procedural aspects for the consultation to the European Medicines...
Regulatory Affairs
23 Apr 2024
New EMA Guideline on Environmental Risk Assessment for Human Medicinal Products
New guideline from the European Medicines Agency (EMA) on the Environmental Risk Assessment of...
Regulatory Affairs
4 Dec 2025
New Update of Appendix 1 of the Nitrosamines Guideline - EMA/42261/2025/Rev. 11
What's new? This update introduces the Acceptable Intake (AI) values for new nitrosamine drug...
Regulatory Affairs
9 Jul 2024
New Update of Appendix 1 of the Nitrosamines Guideline
What’s new? In this update, the Acceptable Intake (AI) values for nitrosamines related to the use...
Regulatory Affairs
14 May 2024
Latest Update on Appendix 1 of the Nitrosamine Guidelines
On 01/05/2024, the European Medicines Agency (EMA) rolled out an update to Appendix 1...
Regulatory Affairs
27 Jan 2025
New revision to EMA Guidance documents released
Both documents, Guidance on the procedural aspects for the consultation to the European Medicines...
Regulatory Affairs
23 Apr 2024
New EMA Guideline on Environmental Risk Assessment for Human Medicinal Products
New guideline from the European Medicines Agency (EMA) on the Environmental Risk Assessment of...
Regulatory Affairs
4 Dec 2025
New Update of Appendix 1 of the Nitrosamines Guideline - EMA/42261/2025/Rev. 11
What's new? This update introduces the Acceptable Intake (AI) values for new nitrosamine drug...
Regulatory Affairs
9 Jul 2024
New Update of Appendix 1 of the Nitrosamines Guideline
What’s new? In this update, the Acceptable Intake (AI) values for nitrosamines related to the use...
Regulatory Affairs
14 May 2024
Latest Update on Appendix 1 of the Nitrosamine Guidelines
On 01/05/2024, the European Medicines Agency (EMA) rolled out an update to Appendix 1...
Regulatory Affairs
27 Jan 2025
New revision to EMA Guidance documents released
Both documents, Guidance on the procedural aspects for the consultation to the European Medicines...
Regulatory Affairs
23 Apr 2024
New EMA Guideline on Environmental Risk Assessment for Human Medicinal Products
New guideline from the European Medicines Agency (EMA) on the Environmental Risk Assessment of...
Next
- 1
- 2
- 3
Stay ahead in life sciences
Keeping up with the fast-paced life sciences industry doesn’t have to be overwhelming.
Our newsletter delivers the latest insights, industry updates, and expert content directly to your inbox, helping you stay informed and make smarter decisions.
Twitter Widget Iframe